Table 1 Characteristics of included studies
Author (year) | Country | Study design | Health conditions | Age (years) | Gender (% of male) | Sample size | Valuation method | Proxy type | |
|---|---|---|---|---|---|---|---|---|---|
Direct | Indirect | ||||||||
Cardarelli (2006) | Italy | CS | Brain tumour/mixed cancer diagnosis/leukaemia/lymphoma | R: 12–28 | NA | 184 |  | HUI2 | Parents |
Fu (2006) | 4 countries | CS | Mixed cancer diagnosis | R: 3.4–25.8; Median: 12.8 | 56.0% | 680 |  | HUI2; HUI3 | Parents; clinicians |
Glaser (1999) | UK | CS | Brain tumour | R: 10–16 | NA | 153 |  | HUI2; HUI3 | Parents; clinicians |
Penn (2011) | UK | L | Brain tumour/general | Brain tumour: R: 3.6–16.4; Median: 11.1 General: R: 5.1–18.9; Median: 10.7 | NA | 43 |  | HUI3 | Parents |
Verrips (2001) | Netherlands | C | VLBW/VP | M: 14.3 | NA | 406 | Â | HUI3 | Parents |
Wolke (2013) | Germany | C | VLBW/VP/general | M: 13 | VLBW/VPT: 55.2% General: 49.5% | 542 | Â | HUI3 | Parents |
Saigal (1999) | Canada | C | ELBW/EP | M(SD): 14.2(1.6) | NA | 1,056 | SG | Â | Parents |
Lee (2011) | USA | C | Diabetes | HUI3: R:8–18; M(SD): 13.7(3.1) TTO: R: 15–18 | NA | 326 | TTO | HUI3 | Parents |
Belfort (2011) | USA | CS | Overweight or obese/general | Overweight or obese: R:8–17; 12–17 General: R:8–18; 8–18 | NA | 304 |  | HUI3 | Parents |
Brunner (2003) | Canada | CS | MSKD | R: 8–18 | NA | 202 | SG; VAS | HUI3 | Parents |
Brunner (2004) | USA | L | MSKD | R: 3–18 | NA | 410 | SG; VAS |  | Parents |
Czyzewski (1994) | USA | CS | Cystic fibrosis | R: 0.2–17.9; M(SD): 8.74(4.86) | NA | 55 |  | QWB | Parents |
Gerald (2012) | USA | CS | Asthma | R: 6–12 | 63.6% | 2,806 |  | PAHOM | Parents |
Kulpeng (2013) | Thailand | C | Bacteremia/epilepsy/hearing loss/lung disease/meningitis/otitis media | R: 5–14 | NA | 296 | EQ-5D; VAS | EQ-5D; HUI3; HUI2 | Caregivers |
Trent (2011) | USA | C | Pelvic inflammatory disease | R: 12–19 | 0% | 1,340 | TTO; VAS |  | Parents |
Sung (2004) | Canada | CS | Asthma/Chronic illness/Injury/Stroke | R: 12–18; M(SD): 13.7(1.7) | 55.0% | 235 | SG; TTO; VAS | HUI2; HUI3 | Parents |
Jelsma-Ramma (2010) | South Africa | C | Chronic illness/general | R: 7–12 | Chronic illness: 74.0% General: 45.0% | 628 | EQ-5D-Y; VAS |  | Parents |
Vermeulen (2017) | Netherlands | C | ODD/CD/DBD/ODD + ADHD/CD + ADHD/DBD + ADHD/ODD + SA/CD + SA | R: 4–12; M:9; R:12–18; M:15 | NA | 688 | EQ-5D-3L; VAS |  | Parents |
Baumann (2016) | Germen | L | VLBW/VPT/General | VLBW/VPT: M:13; 26 General: M:13; 26 | VLBW/VPT: 45.3% General: 53.7% | 792 | Â | HUI3 | Parents |
Robertson (2016) | England | L | Overweight or obese | R: 6–11; M(SD): 9.43(1.61) | 42.9% | 626 | VAS | EQ-5D-Y | Parents |
Hanberger (2009) | Sweden | C | Diabetes | R: 2.6–19.6; M(SD): 13.2(3.9) | 52.3% | 148 |  | EQ-5D | Parents |
Rhodes (2012) | USA | C | Diabetes | R: 12–18; M(SD): 15.5(2) | 32.9% | 107 |  | HUI3 | Parents |
Sims-williams (2017) | Uganda | C | Spina bifida | R: 10–14 | 56.0% | 125 | VAS | HUI3 | Caregivers |
Medeiros (2019) | North America | C | Medulloblastoma | R: 0.33–14.95; 1–17; M(SD): 6.82(3.41); 6.48(3.9) | 68.0%; 76.0% | 152 |  | HUI2; HUI3 | Parents |
Kirkham (2019) | 4 countries | C | Prolonged acute convulsive seizures | R: 13–16; M(SD): 8.8(3.8) | 54.9% | 54 |  | EQ-5D-3L | Parents; clinicians |
Lopez-Bastida (2019) | Spain | C | Diabetes | M(SD): 10.5(3.9); 11.7(3.9); 10.8(4); 11.9(3.4); 11(3.9) | 52.8%; 53.7%; 56%; 43.1%; 53.2% | 801 | EQ-5D-Y VAS | Â | Caregivers |
Perez-Sousa (2018) | Spain | L | Overweight or obese | R: 6–14; 6–13; M(SD): 9.6(2.1); 8.7(1.6) | 55.0%; 47.0% | 302 | EQ-5D-Y VAS |  | Parents |
Bray (2017) | UK | C | Paediatric mobility impairment | R: 6–15; 16–18; 6–18 | 38.5% | 100 | EQ-5D VAS | EQ-5D-Y; HUI2; HUI3 | Parents |
Creswell (2017) | UK | L | Anxiety disorders | M(SD): 9.28(1.83) | 47.0% | 339 | Â | CHU-9D | Parents |
Shi (2017) | Japan | L | General | M: 11.46 | 50.0% | 1,308 | EQ-5D VAS | Â | Parents |